ITCC-037 DABRAFENIB
Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advanced BRAF V600-Mutation Positive Solid Tumors
Promotor Name : GlaxoSmithKline
Investigator Name : B. GEOERGER
Trial registered on clinicaltrial.gov: NCT01677741